Literature DB >> 19214406

[ESC/EASD joint guidelines on diabetes and cardiovascular diseases].

Wolfgang Motz1, Rolf Dörr.   

Abstract

The ESC/EASD (European Society of Cardiology/European Association for the Study of Diabetes) joint Guidelines on diabetes, pre-diabetes, and cardiovascular diseases have, for the first time, addressed diabetes mellitus and cardiovascular diseases (CVD) as a pathophysiological entity in Europe. Based on these guidelines, diabetes mellitus is regarded from the outset to be a cardiovascular disease, whose life-threatening complications myocardial infarction and stroke can only be avoided by an interdisciplinary concerted action. The most important information of these guidelines for the interdisciplinary cooperation of primary-care physicians, diabetologists and cardiologists are the postulations that patients with the main diagnosis diabetes mellitus with or without known CVD should, at regular intervals, be referred to a cardiologist, and patients with the main diagnosis CVD with or without diabetes mellitus should, at regular intervals, be referred to a diabetologist. Of fundamental importance is the prevention of diabetes and CVD by a comprehensive lifestyle modification including smoking cessation, regular physical activity and weight control, flanked by an evidence-based drug therapy. Within the framework of a multimodal risk management, an optimal antihypertensive therapy of a concomitant elevated blood pressure; a statin therapy in case of elevated LDL cholesterol or regardless of an elevated LDL in proven CVD; ACE inhibitors, angiotensin II receptor blockers, or beta-blockers in case of heart failure; and an anticoagulant therapy for the prevention of cardioembolic stroke in patients with atrial fibrillation all have class I recommendations. Concerning the preferred coronary revascularization procedure in diabetics, today no rigid general recommendation can be given in favor of or against coronary bypass surgery, or in favor of or against percutaneous coronary intervention. The decision for a specific revascularization procedure should, in any case, be based on a detailed analysis of the individual coronary anatomy.

Entities:  

Mesh:

Year:  2009        PMID: 19214406     DOI: 10.1007/s00059-009-3203-z

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  52 in total

1.  Actual clinical practice of exercise testing in consecutive patients after non-ST-elevation myocardial infarction: results of the acute coronary syndromes registry.

Authors:  Harm Wienbergen; Anselm Kai Gitt; Rudolf Schiele; Claus Juenger; Tobias Heer; Martin Gottwik; Joachim Manthey; Albrecht Hempel; Kurt Bestehorn; Jochen Senges; Bernhard Rauch
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2006-06

2.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

3.  Glucose tolerance and blood pressure: long term follow up in middle aged men.

Authors:  V V Salomaa; T E Strandberg; H Vanhanen; V Naukkarinen; S Sarna; T A Miettinen
Journal:  BMJ       Date:  1991-03-02

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 6.  [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].

Authors:  Sigmund Silber; Christian Herdeg
Journal:  Herz       Date:  2008-04       Impact factor: 1.443

Review 7.  Cardiac consequences of diabetes mellitus.

Authors:  A Shehadeh; T J Regan
Journal:  Clin Cardiol       Date:  1995-06       Impact factor: 2.882

Review 8.  Cardiovascular complications in diabetes: targets and interventions.

Authors:  Alin O Stirban; Diethelm Tschoepe
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

Review 9.  The management of hypertension in diabetes: with special reference to diabetic kidney disease.

Authors:  G P Leese; J P Vora
Journal:  Diabet Med       Date:  1996-05       Impact factor: 4.359

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more
  3 in total

1.  [Guidelines -- substitute textbook guidelines for daily or limited use?].

Authors:  Bernhard Maisch; Rolf Dörr
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

2.  [Prevalence of undetected diabetes mellitus in invasive and interventional cardiology. Silent diabetes in the catheterization laboratory].

Authors:  R Dörr; J Stumpf; S G Spitzer; B Krosse; D Tschöpe; T Lohmann; O Schnell
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

3.  [Bypass surgery versus percutaneous coronary intervention in patients with diabetes mellitus].

Authors:  Rolf Dörr
Journal:  Herz       Date:  2010-05       Impact factor: 1.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.